23.5 C
New York
Thursday, July 3, 2025

Tag: HEA BIO MTC PHA

HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach

TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology...

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

Phase 3 study met primary and most key secondary clinical endpointsThis marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase...

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today...

Indivior Appoints Tony Kingsley to the Board of Directors

RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of...

LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma

Expanding track record by signing contracts with various global companies across Asia and EuropeSEOUL, South Korea, June 18, 2025 /PRNewswire/ -- LOTTE BIOLOGICS announced...

CureLab Veterinary’s ElenaVet™ Gene Therapy Delivers 90% Success in Pet-Dog Osteoarthritis Study

Frontiers in Veterinary Science paper reports rapid, significant pain relief with weekly p62-plasmid injections and no significant side-effects BOSTON, June 13, 2025 /PRNewswire/ -- CureLab...

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative...

Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025

BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation...

Formation Bio Announces First Class of Entrepreneurs in Residence to Drive Pipeline Growth and Strategic Partnerships

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first...

Axio BioPharma and Likarda Announce Strategic Partnership to Accelerate Biologic Drug Development and Delivery

Partnership combines AI-powered protein manufacturing with advanced drug delivery technologies to accelerate timelines and improve therapeutic outcomes. MADISON, Wis. and KANSAS CITY, Mo., June 9,...

BIOSeedin Innovation Partnering Conference 2025: Spotlight on China’s Biopharma Trailblazers and Global Collaboration

NEWARK, Del., June 5, 2025 /PRNewswire/ -- China's influential innovative drug asset cooperation platform BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHEA BIO MTC PHA